Literature DB >> 27570115

Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma.

J-W Xie1, Y-Q Sun1, C-Y Feng2, C-H Zheng1, P Li1, J-B Wang1, J-X Lin1, J Lu1, Q-Y Chen1, L-L Cao1, M Lin1, R-H Tu1, Y-H Yang3, C-M Huang4.   

Abstract

BACKGROUND: Research on the clinicopathology and prognosis of gastric neuroendocrine carcinoma (GNEC) is rare, and a uniform standard for treatment has not been established. Therefore, we retrospectively analyzed the clinical data of 132 cases of GNEC to investigate the factors influencing prognosis.
METHODS: A total of 132 patients diagnosed with GNEC at Fujian Medical University Union Hospital from January 2006 to December 2013 were enrolled. This study was performed to analyze the factors related to patient prognosis.
RESULTS: In total, 58 men and 74 women whose ages ranged from 38 to 83 years old (62 ± 10) were enrolled. The 1- and 3-year survival rates for these patients were 83.9% and 47.6%, respectively. Of these patients, 100 underwent radical resection, 22 underwent palliative resection, and 10 received chemotherapy alone. The median survival times following radical resection, palliative resection and chemotherapy alone were 48, 20 and 12 months, respectively (P < 0.01). Univariate and multivariate survival analyses of patients who underwent radical resection showed that tumor size, N stage, Ki-67 labeling index, mitotic index and the application of postoperative adjuvant chemotherapy were independent factors affecting patient prognosis. The correlation analysis of the Ki-67 labeling index and mitotic index with prognosis showed that patient survival decreased significantly when the Ki-67 labeling index increased (P < 0.05).
CONCLUSIONS: Patients who underwent radical resection had the best prognosis among GNEC. For these patients, tumor size, N stage, Ki-67 labeling index, mitotic index and the application of postoperative adjuvant chemotherapy were the clinicopathological factors significantly associated with patient prognosis.
Copyright © 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Gastric neoplasm; Neuroendocrine tumor; Prognosis; Radical resection

Mesh:

Substances:

Year:  2016        PMID: 27570115     DOI: 10.1016/j.ejso.2016.08.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

Review 1.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

2.  Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research.

Authors:  Ping Hu; Jian'an Bai; Min Liu; Jingwen Xue; Tiaotiao Chen; Rui Li; Xiaoling Kuai; Haijian Zhao; Xiaolin Li; Ye Tian; Wei Sun; Yujia Xiong; Qiyun Tang
Journal:  Gastric Cancer       Date:  2020-02-05       Impact factor: 7.370

3.  Predictive Value of Combined Preoperative Carcinoembryonic Antigen Level and Ki-67 Index in Patients With Gastric Neuroendocrine Carcinoma After Radical Surgery.

Authors:  Jianwei Xie; YaJun Zhao; Yanbing Zhou; Qingliang He; Hankun Hao; Xiantu Qiu; Gang Zhao; Yanchang Xu; Fangqin Xue; Jinping Chen; Guoqiang Su; Ping Li; Chao-Hui Zheng; Chang-Ming Huang
Journal:  Front Oncol       Date:  2021-03-02       Impact factor: 6.244

4.  The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.

Authors:  Bin Xu; Yuxin Chu; Qinyong Hu; Qibin Song
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.

Authors:  Arvind Dasari; Chan Shen; Anjali Devabhaktuni; Ruda Nighot; Halfdan Sorbye
Journal:  Oncologist       Date:  2022-04-05

6.  RUNDC3A regulates SNAP25-mediated chemotherapy resistance by binding AKT in gastric neuroendocrine carcinoma (GNEC).

Authors:  Pengchen Chen; Wei Wang; Sin Wa Wong; Junnan Li; Qiushaung Wu; Shu-Dong Zhang; Yao Lin; Hang Fai Kwok
Journal:  Cell Death Discov       Date:  2022-06-25

7.  Mixed large and small cell neuroendocrine carcinoma of the stomach: A case report and review of literature.

Authors:  Ze-Feng Li; Hai-Zhen Lu; Ying-Tai Chen; Xiao-Feng Bai; Tong-Bo Wang; He Fei; Dong-Bing Zhao
Journal:  World J Clin Cases       Date:  2022-06-06       Impact factor: 1.534

8.  Neuroendocrine carcinoma of the gastric stump: A case report and literature review.

Authors:  Fu-Hai Ma; Li-Yan Xue; Ying-Tai Chen; Yi-Bin Xie; Yu-Xin Zhong; Quan Xu; Yan-Tao Tian
Journal:  World J Gastroenterol       Date:  2018-01-28       Impact factor: 5.742

9.  Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients.

Authors:  Jian-Wei Xie; Jun Lu; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Chao-Hui Zheng; Ping Li; Chang-Ming Huang
Journal:  BMC Cancer       Date:  2018-10-22       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.